

Sustained Release Injectables

Evolving Formulations, Improving Dosing Regimens



Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens

Greystone Research Associates is pleased to announce the publication of a new market study. **Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens** is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the therapeutic drug sector.

The study is designed to provide drug company decision makers, drug developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for sustained release injectable drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Drug Safety, Patient Compliance and Injectable Drug Dosing

The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency addresses several important health care issues. Less frequent dosing is believed to improve patient safety, reduce the incidence of injection site complications and improve compliance with drug protocols. Sustained release formulations mitigate the bolus effect at the time of injection, and thus have a salutary influence on drug side effects. All of these advantages, along with the need for fewer patient caregiver visits (for practitioner-administered drugs) have a positive, downward impact on overall healthcare costs. Currently approved sustained release injectables rely on a spectrum of branded formulation technologies to modulate the drug's release profile post-injection. Typically off-patent or generic drugs, they include drug therapies for almost a dozen major therapeutic segments, including neurological conditions, metabolic diseases, oncology, pain management and reproductive health. As the incidence and prevalence of chronic illnesses increases with the aging population, the attraction and interest in sustained release injectables will increase.

Report Value Matrix




Table of Contents

Executive Summary

Injectable Drug Market Dynamics

The Trend toward Self-Administration
Shifting Demographics
Injectable Drug Formulation Technology
Innovation in Injectable Device Designs
Therapeutic Demand Drivers
Competitive Landscape
Risk Factors

Sustained Release Injectables - Branded Formulation Technologies

Biodegradable Polymers

PEG

PLG/PLA/PLGA

Polyether ester

ChroniJect

CriticalMix

Depofoam

LinkeRx

Liposomes

Medisorb

Medusa

Optisomes

OxtoDEX

SABER/SAIB

Sucrose acetate isobutyrate

SynBiosys

Supercritical Fluid

Analysis of FDA Approved Sustained Release Injectables

cytarabine

goserelin acetate

Interferon

lanreotide acetate

leuprolide acetate

morphine

naltrexone

olanzapine

octreotide acetate

risperidone

paliperidone palmitate

somatostatin

triptorelin pamoate

Development-Stage SR Injectable Drug Candidate Assessment

- Addiction
- Antivirals
- Hormones
- Immune Modulators
- Incretin Mimetics
- Local Anesthetics
- Opioid Antagonists
- Psychotropics
- Antineoplastics

SR Injectables – Therapeutic Sector Impact Analysis & Forecasts

- Addiction
- Autoimmune Diseases
- Diabetes
- Infectious Disease
- Macular Degeneration
- Metabolic Diseases
- Neurology
- Oncology
- Pain Management
- Reproductive Health

Sustained Release Injectables – Company Profiles

Feature Summary

- Provides detailed analysis of sustained release injectable products, market segments, market dynamics and market demographics
- Analyzes therapeutic demand drivers and evaluates commercial sustained release injectables in eleven major therapeutic segments
- Analyzes design factors, material selection issues, technologies and market development issues
- Charts sustained release product data and market share, and provides forecasts to 2015
- Profiles sustained release technology participants, their product development activities, business strategies, and corporate alliances and affiliations
- Assesses the importance of pharma-device alliances and partnerships on sustained release injectable drugs
- Evaluates the impact of economic, technology, and regulatory factors

Report Format and Availability

This report is available in electronic format. A site license for a single physical location and an Enterprise license are also available.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

About Greystone Research Associates

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address. Orders which are not prepaid must indicate the billing address. There is no charge for handling and shipping for destination addresses within the continental US.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express

Wire Transfers: See 'Wire Transfers' below for more information

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer. There is a \$50 per copy shipping and handling charge for international shipments.

Wire Transfers: TD Banknorth
300 Franklin Street
Manchester, NH 03103
(Call for Account Information)

Mailing Address: Greystone Associates
Client Services
P.O. Box 1362
Amherst, NH 03031

Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens

Select	Format	Price (U.S. funds)	Total
<input type="checkbox"/>	Electronic	\$3,850.00	
<input type="checkbox"/>	Site License	\$5,500.00	
<input type="checkbox"/>	Enterprise License	\$8,500.00	
Total Payment (U.S. funds)			

Method of Payment: Company Check    Wire Transfer (International)

Card Number: _____ Name on Card _____

Expiration Date: _____ Card CVV _____ Signature _____

Billing Information	Shipping Information
	<input type="checkbox"/> Click here if same as Billing Information
Name:	Name:
Title:	Title:
Company:	Company:
Street Address:	Street Address:
City,State/Province:	City,State/Province:
Country/Postal Code:	Country/Postal Code:
Phone:	Phone:
Fax:	Fax:
Email:	Email: